Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Inclusion Criteria: * CNV of less than 1 year duration due to presumed ocular histoplasmosis * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age 21 years and older * Subfoveal or juxtafoveal CNV lesion of less than 5400um in diameter * Best corrected visual acuity of 20/25 to 20/400 * Birth control therapy for females of child-bearing age Exclusion Criteria: * CNV due to presumed ocular histoplasmosis for greater than 1 year * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception. The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch * A recent history of smoking (within 1 year of study enrollment) * Prior treatment with intravitreal aflibercept injection * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Uncontrolled glaucoma in the study eye (defined as IOP greater or equal to 30 mmHg despite treatment with anti-glaucoma medication) * History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Presenc…